All In Biotech

Drug Trial Radar · NCT06079281

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 (Recombinant Alkaline Phosphatase) Administered Subcutaneously in Adolescent (12 to < 18 Years of Age) and Adult Participants With Hypophosphatasia Who Have Not Previously Been Treated With Asfotase Alfa

Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

124

Actual

Start

Jan 3, 2024

Primary completion

Jul 9, 2025

Study completion Mar 29, 2028

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.

Conditions

  • Hypophosphatasia

Interventions

  • ALXN1850Drug

    ALXN1850 will be administered via subcutaneous (SC) injection.

  • PlaceboDrug

    Placebo will be administered via SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in 6-Minute Walk Test (6MWT) at the end of the Randomized Evaluation Period (Day 169)Time frame: Baseline, Day 169

Locations

65 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Garden City, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Columbus, Ohio

  • Research Site

    Nashville, Tennessee

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Clayton, Australia

  • Research Site

    Herston, Australia

  • Research Site

    Parkville, Australia

  • Research Site

    St Leonards, Australia

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Brasília, Brazil

  • Research Site

    Recife, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Winnepeg, Manitoba, Canada

  • Research Site

    Oakville, Ontario, Canada

  • Research Site

    Trois-Rivières, Quebec, Canada

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Nanchang, China

  • Research Site

    Qingdao, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenzhen, China

  • Research Site

    Paris, France

  • Research Site

    Poitiers, France

  • Research Site

    Bad Reichenhall, Germany

  • Research Site

    Berlin, Germany

  • Research Site

    Bonn, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Würzburg, Germany

  • Research Site

    Ashkelon, Israel

  • Research Site

    Ramat Gan, Israel

  • Research Site

    Florence, Italy

  • Research Site

    Milan, Italy

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.